Programmed necrotic cell death induced by complement involves a bid-dependent pathway

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 515-521

  Ziporen, Lea ^a   Donin, Natalie ^a   Shmushkovich, Taisia ^a   Gross, Atan ^b   Fishelson, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CALCIMYCIN; CASPASE; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; MELITTIN; PROTEIN BID; PROTEIN CRRY; STREPTOLYSIN O; UNCLASSIFIED DRUG; BID PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN K 562; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DEATH; CELL LINE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE MUTANT; NECROSIS; NEWBORN; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASES; CELL DEATH; CELL LINE, TRANSFORMED; CELLS, CULTURED; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBROBLASTS; HUMANS; IMMUNITY, INNATE; JURKAT CELLS; K562 CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; SIGNAL TRANSDUCTION;

EID: 59849101189     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.515     Document Type: Article

References (40)

1. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
2. Muller-Eberhard, H. J. 1986. The membrane attack complex of complement. Annu. Rev. Immunol. 4: 503-528.
3. Koski, C. L., L. E. Ramm, C. H. Hammer, M. M. Mayer, and M. L. Shin. 1983. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc. Natl. Acad. Sci. USA 80: 3816-3820.
4. Papadimitriou, J. C., C. B. Drachenberg, M. L. Shin, and B. F. Trump. 1994. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch. 424: 677-685.
5. 2+ on the lytic process. J. Immunol. 138: 1530-1536.
6. Rus, H. G., F. Niculescu, and M. L. Shin. 1996. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156: 4892-4900.
7. Morgan, B. P. 1989. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264: 1-14.
8. Bohana-Kashtan, O., L. Ziporen, N. Donin, S. Kraus, and Z. Fishelson. 2004. Cell signals transduced by complement. Mol. Immunol. 41: 583-597.
9. Fishelson, Z., G. Attali, and D. Mevorach. 2001. Complement and apoptosis. Mol. Immunol. 38: 207-219.
10. Reiter, Y., A. Ciobotariu, and Z. Fishelson. 1992. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur. J. Immunol. 22: 1207-1213.
11. Soane, L., H. Rus, F. Niculescu, and M. L. Shin. 1999. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase- 3 activation. J. Immunol. 163: 6132-6138.
12. Nauta, A. J., M. R. Daha, O. Tijsma, B. van de Water, F. Tedesco, and A. Roos. 2002. The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 32: 783-792.
13. Attali, G., D. Gancz, and Z. Fishelson. 2004. Increased sensitivity of early apoptotic cells to complement-mediated lysis. Eur. J. Immunol. 34: 3236-3245.
14. Contreras, J. L., G. Bilbao, C. Smyth, D. E. Eckhoff, X. L. Xiang, S. Jenkins, S. Cartner, D. T. Curiel, F. T. Thomas, and J. M. Thomas. 2001. Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery 130: 166-174.
15. Ramanarayanan, J., F. J. Hernandez-Ilizaliturri, A. Chanan-Khan, and M. S. Czuczman. 2004. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br. J. Haematol. 127: 519-530.
16. Hussain, S. R., C. M. Cheney, A. J. Johnson, T. S. Lin, M. R. Grever, M. A. Caligiuri, D. M. Lucas, and J. C. Byrd. 2007. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res. 13: 2144-2150.
17. Yin, X. M. 2006. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 369: 7-19.
18. Lachmann, P. J., and R. A. Thompson. 1970. Reactive lysis: the complement-mediated lysis of unsensitized cells: II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Exp. Med. 131: 643-657.
19. 2+ in complement membrane attack. Cell Calcium 7: 399-411.
20. 2+ deregulation on mitochondrial membrane potential and cell viability in nucleated cells following lytic complement attack. Cell Calcium 15: 217-227.
21. Syntichaki, P., and N. Tavernarakis. 2002. Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? EMBO Rep. 3: 604-609.
22. Proskuryakov, S. Y., A. G. Konoplyannikov, and V. L. Gabai. 2003. Necrosis: a specific form of programmed cell death? Exp. Cell Res. 283: 1-16.
23. Zong, W. X., and C. B. Thompson. 2006. Necrotic death as a cell fate. Genes Dev. 20: 1-15.
24. Holler, N., R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider, B. Seed, and J. Tschopp. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1: 489-495.
25. Kawahara, A., Y. Ohsawa, H. Matsumura, Y. Uchiyama, and S. Nagata. 1998. Caspase-independent cell killing by Fas-associated protein with death domain. J. Cell Biol. 143: 1353-1360.
26. Vercammen, D., R. Beyaert, G. Denecker, V. Goossens, G. Van Loo, W. Declercq, J. Grooten, W. Fiers, and P. Vandenabeele. 1998. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187: 1477-1485.
27. Chan, F. K., J. Shisler, J. G. Bixby, M. Felices, L. Zheng, M. Appel, J. Orenstein, B. Moss, and M. J. Lenardo. 2003. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J. Biol. Chem. 278: 51613-51621.
28. Reiter, Y., A. Ciobotariu, J. Jones, B. P. Morgan, and Z. Fishelson. 1995. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J. Immunol. 155: 2203-2210.
29. Kraus, S., and Z. Fishelson. 2000. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur. J. Immunol. 30: 1272-1280.
30. Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116: 205-219.
31. Korsmeyer, S. J., M. C. Wei, M. Saito, S. Weiler, K. J. Oh, and P. H. Schlesinger. 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7: 1166-1173.
32. Reed, J. C. 2006. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13: 1378-1386.
33. Zinkel, S., A. Gross, and E. Yang. 2006. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13: 1351-1359.
34. Li, H., H. Zhu, C.-j. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501.
35. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
36. Gross, A., X. M. Yin, K. Wang, M. C. Wei, J. Jockel, C. Milliman, H. Erdjument-Bromage, P. Tempst, and S. J. Korsmeyer. 1999. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274: 1156-1163.
37. Guo, Y., S. M. Srinivasula, A. Druilhe, T. Fernandes-Alnemri, and E. S. Alnemri. 2002. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem. 277: 13430-13437.
38. Porn-Ares, M. I., T. C. Saido, T. Andersson, and M. P. Ares. 2003. Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells. Biochem. J. 374: 403-411.
39. Sarig, R., Y. Zaltsman, R. C. Marcellus, R. Flavell, T. W. Mak, and A. Gross. 2003. BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts. J. Biol. Chem. 278: 10707-10715.
40. Cudrici, C., F. Niculescu, T. Jensen, E. Zafranskaia, M. Fosbrink, V. Rus, M. L. Shin, and H. Rus. 2006. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J. Immunol. 176: 3173-3180.